NIFEDIPINE (nifedipine) by Charter Medical is calcium channel antagonists [moa]. Approved for vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina, coronary artery spasm provoked by ergonovine and 4 more indications. First approved in 2017.
Drug data last refreshed 1w ago
Calcium Channel Antagonists
Dihydropyridine Calcium Channel Blocker
Worked on NIFEDIPINE at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension